Rosebengal Assisted Antimicrobial Photodynamic Therapy as an Adjunct To Mechanical Debridement In Non Surgical Management Of Periimplantitis- A Randomised Control Trial. - Nil

开始日期2024-04-25

申办/合作机构-

IRCT20100919004775N14 / RecruitingN/AIIT

The effect of aromatherapy with rose on anxiety and pain of patients before and after Endoscopic lithotripsy procedure

开始日期2022-10-23

申办/合作机构

Shiraz University of Medical Sciences

NCT05110001 / Active, not recruiting临床3期IIT

Rose Bengal Electromagnetic Activation With Green Light for Infection Reduction

Rose Bengal Electromagnetic Activation with Green light for Infection Reduction (REAGIR ) is an international, randomized, doubled masked, clinical trial. The purpose of this study is to determine differences in 6-month visual acuity between medical antimicrobial treatments alone versus antimicrobial treatment plus cross-linking with rose Bengal (RB-PDT).
Patients presenting to one of the Aravind Eye Hospitals in India or to the Federal University of São Paulo ophthalmology clinic in Brazil with either smear or culture positive fungal or acanthamoeba keratitis or smear and culture negative corneal ulcers and moderate to severe vision loss, defined as Snellen visual acuity of 20/40 or worse, will be eligible for inclusion. Those who agree to participate will be randomized to one of two treatment groups:
Group 4, Sham RB-PDT: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus sham RB-PDT
Group 5, RB-PDT: topical chlorhexidine gluconate 0.02% (acanthamoeba), moxifloxacin 0.5% (smear/culture negative) or natamycin 5% (fungal keratitis) plus RB-PDT.

开始日期2022-08-03

申办/合作机构

The University of California, San Francisco

[+4]

100 项与 Rose Bengal disodium 相关的临床结果

登录后查看更多信息

100 项与 Rose Bengal disodium 相关的转化医学

登录后查看更多信息

100 项与 Rose Bengal disodium 相关的专利（医药）

登录后查看更多信息

1,168

项与 Rose Bengal disodium 相关的文献（医药）

2024-02-01·Plant physiology and biochemistry : PPB

Modification in the ascorbate-glutathione cycle leads to a better acclimation to high light in the rose Bengal resistant mutant of Nannochloropsis oceanica

Article

作者: Khozin-Goldberg, Inna ; Li, Yu-Chia ; Chen, Jen-Chih ; Tsai, Tsung-Yu ; Chien, Yi-Lin ; Zheng, Yu-Yun ; Vonshak, Avigad ; Su, Ruey-Chih ; Lee, Tse-Min ; Ben-Sheleg, Avraham

Understanding how to adapt outdoor cultures of Nannochloropsis oceanica to high light (HL) is vital for boosting productivity. The N. oceanica RB2 mutant, obtained via ethyl methanesulfonate mutagenesis, was chosen for its tolerance to Rose Bengal (RB), a singlet oxygen (¹O₂) generator. Compared to the wild type (WT), the RB2 mutant showed higher resilience to excess light conditions. Analyzing the ascorbate-glutathione cycle (AGC), involving ascorbate peroxidases (APX, EC 1.11.1.11), dehydroascorbate reductase (DHAR, EC 1.8.5.1), and glutathione reductase (GR, EC 1.8.1.7), in the RB2 mutant under HL stress provided valuable insights. At 250 μmol photon m^-2 s^-1 (HL), the WT strain displayed superoxide anion radicals (O₂^▪-) and hydrogen peroxide (H₂O₂) accumulation, increased lipid peroxidation, and cell death compared to normal light (NL) conditions (50 μmol photon m^-2 s^-1). The RB2 mutant didn't accumulate O₂^▪- and H₂O₂ after HL exposure, and exhibited increased APX, DHAR, and GR activities and transcript levels compared to WT and remained consistent after HL treatment. Although the RB2 mutant had a smaller ascorbate (AsA) pool than the WT, its ability to regenerate dehydroascorbate (DHA) increased post HL exposure, indicated by a higher AsA/DHA ratio. Additionally, under HL conditions, the RB2 mutant displayed an improved glutathione (GSH) regeneration rate (GSH/GSSG ratio) without changing the GSH pool size. Remarkably, H₂O₂ or menadione (a O₂^▪- donor) treatment induced cell death in the WT strain but not in the RB2 mutant. These findings emphasize the essential role of AGC in the RB2 mutant of Nannochloropsis in handling photo-oxidative stress.

2024-02-01·Pest management science

Larvicidal activity of the photosensitive insecticides, methylene blue and rose bengal, in Aedes aegypti and Anopheles gambiae mosquitoes

Article

作者: Meier, Cole J ; Hillyer, Julián F

Abstract:

BACKGROUND:

Insecticides are critical for controlling mosquito populations and mitigating the spread of vector‐borne disease, but their overuse has selected for resistant populations. A promising alternative to classical chemical insecticides is photosensitive molecules – here called photosensitive insecticides or PSIs – that when ingested and activated by light, generate broadly toxic reactive oxygen species. This mechanism of indiscriminate oxidative damage decreases the likelihood that target site modification‐based resistance evolves. Here, we tested whether the PSIs, methylene blue (MB) and rose bengal (RB), are viable insecticides across the mosquito lineage.

RESULTS:

MB and RB are phototoxic to both Aedes aegypti and Anopheles gambiae at micromolar concentrations, with greatest toxicity when larvae are incubated in the dark with the PSIs for 2 h prior to photoactivation. MB is ten times more toxic than RB, and microscopy‐based imaging suggests that this is because ingested MB escapes the larval gut and disperses throughout the hemocoel whereas RB remains confined to the gut. Adding food to the PSI‐containing water has a bidirectional, concentration‐dependent effect on PSI toxicity; toxicity increases at high concentrations but decreases at low concentrations. Finally, adding sand to the water increases the phototoxicity of RB to Ae. aegypti.

CONCLUSION:

2024-01-30·Translational vision science & technology

Combining Riboflavin/UV-A Light and Rose Bengal/Green Light Corneal Cross-Linking Increases the Resistance of Corneal Enzymatic Digestion

Article

作者: Torres-Netto, Emilio A ; Hafezi, Nikki L ; Koppen, Carina ; Hafezi, Farhad ; Lu, Nan-Ji ; Aydemir, M Enes ; Hillen, Mark

Purpose:

The purpose of this study was to determine if concurrent riboflavin/UV-A light (RF/UV-A) and rose Bengal/green light (RB/green) epi-off PACK-CXL enhances corneal resistance to enzymatic digestion compared to separate chromophore/light treatments.

Methods:

Ex vivo porcine corneas were allocated as follows. Group A corneas were soaked with riboflavin (RF) and were either not irradiated (A1, controls) or were irradiated with 10 (A2) or 15 J/cm² (A3) UV-A light at 365 nm, respectively. Group B corneas were soaked with RB and either not irradiated (B1, controls) or were illuminated with 10 (B2) or 15 J/cm² (B3) green light at 525 nm, respectively. Corneas in group C were soaked with both RF and RB and were either not irradiated (C1, controls) or were subjected to the same session consecutive 10 J/cm2 (C2) or 15 J/cm2 (C3) UV-A and green light exposure. Following treatment, all corneas were exposed to 0.3% collagenase A to assess digestion time until corneal button dissolution.

Results:

A1 to A3 digestion times were 21.38, 30.5, and 32.25 hours, respectively, with A2 and A3 showing increased resistance to A1. B1-3 had digestion times of 31.2, 33.81, and 34.38 hours, with B3 resisting more than B1. C1 to C3 times were 33.47, 39.81, and 51.94 hours; C3 exhibited superior resistance to C1 and C2 (both P < 0.05).

Conclusions:

Same-session combined RF/UV-A and RB/green PACK-cross-linking significantly increases corneal enzymatic digestion resistance over standalone treatments.

Translational Relevance:

Combining RF-based and RB-based PACK-CXL considerably increases corneal collagenase digestion resistance, potentially minimizing ulcer size in clinical contexts.

项与 Rose Bengal disodium 相关的新闻（医药）

2024-05-21

·BioSpace

Provectus Biopharmaceuticals Announces Poster Presentation of Rose Bengal Sodium for Treatment of Full-Thickness Cutaneous Wounds at SID 2024 Annual Meeting

Accelerates wound closure and improves wound healing KNOXVILLE, TN, May 21, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that non-clinical data on Provectus’s proprietary, pharmaceutical-grade, rose bengal sodium (“RBS”) active pharmaceutical ingredient for the topical treatment of full-thickness cutaneous wounds were presented at the annual meeting of the Society for Investigative Dermatology (“SID”), held May 15-18, 2024 in Dallas, Texas. This work is part of research being conducted by Amina El Ayadi, PhD, Assistant Professor, Surgical Sciences Division of the Burn, Trauma, and Critical Care Research Laboratory in the Department of Surgery at the University of Texas Medical Branch at Galveston (“UTMB”). A copy of UTMB’s poster presentation is available here: . The UTMB team and Dr. El Ayadi concluded that: The application of multidose 0.01% RBS every other day under ambient light (“RBS treatment”) to full-thickness wounds showed: No toxicity or mortality, No loss in body weight, No organ abnormalities, and No observed adverse effect level at the highest tested dose, Transepidermal water loss was significantly reduced by 14 days, suggesting improvement in skin barrier function, Erythema was increased at seven days, suggesting increased blood flow and granulation tissue formation required for wound healing, Vascularity was increased between three and seven days, supporting pro-angiogenic activity needed for wound closure, RBS treatment: Accelerated wound closure (significant difference at three days), Increased collagen density at seven and 14 days, supporting increased wound remodeling and tissue regeneration, and Reduced angiogenesis after wound closure (day 14), which is beneficial in preventing fibrosis. About University of Texas Medical Branch at Galveston Starting from the Texas City Disaster of 1947, the deadliest industrial accident in U.S. history and one of history’s largest non-nuclear explosions, UTMB clinicians and researchers in the Department of Surgery have developed treatments that improve the survival chances of patients with massive burns, reduce scar formation, and accelerate patient recovery. Many novel treatments discovered by UTMB researchers have been adopted by specialist burn centers around the world. The Department of Surgery’s Burn, Trauma, and Critical Care Research Laboratory is equipped with an array of cutting-edge equipment and technologies that support its research activities, including a dedicated cell culture suite, confocal microscope, flow cytometer, Comprehensive Lab Animal Monitoring System, and bioprinter for 3D cell culture. About Provectus Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium. Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at . FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook. The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels. Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement. Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of the Company’s: Annual Report on Form 10-K for the period ended December 31, 2023, and Quarterly Report on Form 10-Q for the period ended March 31, 2024. ##### Contact: Provectus Biopharmaceuticals, Inc. Heather Raines, CPA Chief Financial Officer Phone: (866) 594-5999

临床结果

2024-05-14

·BioSpace

Provectus Biopharmaceuticals Announces Eight Presentations of Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2024 Annual Meeting

PDAT clinical outcomes for infectious keratitis from Brazil and Mexico KNOXVILLE, TN, May 14, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that clinical and non-clinical data on rose bengal photodynamic antimicrobial therapy (“RB PDAT”) were presented at the annual meeting of the Association for Research in Vision and Ophthalmology (“ARVO”), held May 5-9, 2024 in Seattle, Washington. The ARVO annual meeting brings together approximately 10,000 vision researchers, clinicians, and scientists from around the world for scientific sessions, poster presentations, and invited speaker sessions. Provectus entered into an exclusive worldwide license agreement with the University of Miami (the “University”) in April 2024 for its intellectual property related to RB PDAT for treating bacterial, fungal, and parasitic (acanthamoeba) eye infections. The Company and University plan to form a start-up biotechnology company (e.g., “Eyecare NewCo”), potentially in the third quarter of 2024, aimed at commercializing the University’s PDAT light source medical device in combination with a drug formulation of Provectus’s proprietary pharmaceutical-grade rose bengal active pharmaceutical ingredient (“RB API”). The Company would contribute the RB PDAT license to and have an exclusive RB API supply arrangement with Eyecare NewCo. RB PDAT emerged under the leadership of Jean-Marie Parel, IngETS-G, Ph.D., FARVO, Director of Bascom Palmer Eye Institute’s (“BPEI’s”) Ophthalmic Biophysics Center at the University of Miami Miller School of Medicine. Dr. Parel and the OBC team have spent more than ten years advancing RB PDAT technology against different types of infectious keratitis. ARVO 2024 RB PDAT presentations included: Evaluating the Safety of Rose Bengal Photodynamic Therapy, Huang et al., BPEI (Poster no. B0448, Session: Cornea), Rose Bengal Photodynamic Antimicrobial Therapy as an Adjuvant Treatment for Infectious Keratitis, Eskenazi-Betech et al., Instituto de Oftalmologia Fundacion Conde de Valenciana IAP (Mexico) (B0338, Cornea), Assessment of photosensitizer concentration with a Singlet Oxygen luminescence dosimeter for Photodynamic Antimicrobial Therapy, Carrera et al., BPEI (B0570, Cornea), Clinical outcome in patients with infectious keratitis treated with Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT) at the Federal University of Sao Paulo (UNIFESP), Tabuse et al., Universidade Federal de São Paulo (Brazil) (B0575, Cornea), Enhanced Fungal Inhibition with High-Dose Rose Bengal Photodynamic Antimiocrobial Therapy, Merikansky et al., BPEI (B0580, Cornea), Inhibition of Fungal Isolates via Singlet Oxygen Generation from Erythrosin B and Rose Bengal Photodynamic Antimicrobial Therapy, Ahmed et al., BPEI (Paper no. 4917, Cornea), Arginine-Mediated Enhancement of Photodynamic Antimicrobial Therapy to Target the Oxygen-Independent Pathway, Gonzalez et al., BPEI (B0005, Immunology/Microbiology), and Preclinical/Poster: Exploring the Combination of Rose Bengal Photodynamic Antimicrobial Therapy and Existing Antifungals, Krishna et al., BPEI (B0010, Immunology/Microbiology). RB PDAT is the subject of two international Phase 3 randomized controlled trials for acanthamoeba and fungal (NCT05110001) and bacterial (NCT06271772) keratitis, and has been used to treat infectious keratitis patients in four countries to date: U.S.: BPEI (first clinical reporting: Naranjo et al. 2019), India: LV Prasad Eye Institute (Bagga et al. 2022) and Aravind Eye Care System (NCT05110001 data readout planned in Q4 2024), Brazil: Universidade Federal de São Paulo (ARVO 2024), and Mexico: Instituto de Oftalmología FAP (ARVO 2024). About Bascom Palmer Eye Institute Bascom Palmer Eye Institute serves as the Department of Ophthalmology for the University of Miami Miller School of Medicine. The mission of BPEI is to enhance the quality of life by improving sight, preventing blindness, and advancing ophthalmic knowledge through compassionate patient care and innovative research. For 2023-2024, U.S. News & World Report (“U.S. News”) ranked BPEI as the nation’s best in ophthalmology, marking the 22nd time and 20th consecutive year that BPEI has received the No. 1 ranking since U.S. News began surveying American physicians for its annual “Best Hospitals” rankings 34 years ago. About Provectus Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium. Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at . FORWARD-LOOKING STATEMENTS: The information provided in this press release may include forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, relating to the business of Provectus and its affiliates, which are based on currently available information and current assumptions, expectations, and projections about future events and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Such statements are made in reliance on the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are often, but not always, identified by the use of words such as “aim,” “likely,” “outlook,” “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “would,” “project,” “projection,” “predict,” “potential,” “targeting,” “intend,” “can,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook. The safety and efficacy of Provectus’s drug agents and/or their uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any revenue levels. Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and the Company undertakes no obligation to update or revise any forward-looking statements, whether because of new information, future events, or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement. Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission, including those described in Item 1A of: The Company’s Annual Report on Form 10-K for the period ended December 31, 2023. ##### Contact: Provectus Biopharmaceuticals, Inc. Heather Raines, CPA Chief Financial Officer Phone: (866) 594-5999

引进/卖出临床3期

2024-05-02

·GlobeNewswire-Health Care

Provectus Biopharmaceuticals Announces Notice of Allowance for U.S. Patent of Oral Administration of Rose Bengal Sodium in Hematology (Leukemia)

KNOXVILLE, TN, May 02, 2024 (GLOBE NEWSWIRE) -- Provectus Biopharmaceuticals, Inc. (“Provectus” or the “Company”) (OTCQB: PVCT) today announced that the United States Patent and Trademark Office has allowed patent application 17/232,393, titled “Halogenated Xanthene Composition and Method for Treating Hematologic Cancers” (formerly “Composition and Method for Oral Treatment of Leukemia”). The application covers the use of Provectus’s pharmaceutical grade rose bengal sodium (“RBS”) active pharmaceutical ingredient for the single agent or combination therapy treatment of pediatric and adult leukemias. Earlier this year, Provectus announced notices of allowance and award for U.S. patents of RBS in virology, pediatric solid tumor cancers, and vaccines. Innovate Calgary, the innovation company of the University of Calgary in Alberta, Canada, is a co-assignee and Aru Narendran, MD, PhD, Professor of Pediatrics, Oncology, Biochemistry and Molecular Biology and Physiology and Pharmacology at the University’s Cumming School of Medicine is a co-inventor on all four patent awards. Dominic Rodrigues, President and Vice Chairman of Provectus’s Board of Directors said, “As we remain focused on advancing intratumoral administered cancer immunotherapy PV-10 towards initial drug approval for metastatic pancreatic cancer, our evidence-based confidence in the potential and possibilities of oral administration of rose bengal sodium for the treatment of disease continues to grow.” About Provectus Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company developing immunotherapy medicines for different diseases that are based on a class of synthetic small molecule immuno-catalysts called halogenated xanthenes. Provectus’s lead HX molecule is named rose bengal sodium. Provectus’s medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; proof-of-concept in vivo development programs in oncology, hematology, full-thickness cutaneous wound healing, and canine cancers; and in vitro discovery programs in infectious diseases, tissue regeneration and repair, and proprietary targets. Information about the Company’s clinical trials can be found at the National Institutes of Health (NIH) registry, ClinicalTrials.gov. For additional information about Provectus, please visit the Company’s website at www.provectusbio.com. FORWARD-LOOKING STATEMENTS: The information in this press release may include “forward-looking statements,” within the meaning of U.S. securities legislation, relating to the business of Provectus and its affiliates, which are based on the opinions and estimates of Company management and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “seek,” “anticipate,” “budget,” “plan,” “continue,” “estimate,” “expect,” “forecast,” “may,” “will,” “project,” “predict,” “potential,” “targeting,” “intend,” “could,” “might,” “should,” “believe,” and similar words suggesting future outcomes or statements regarding an outlook. The safety and efficacy of the agents and/or uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated or that such agents as products will achieve any particular revenue levels. Due to the risks, uncertainties, and assumptions inherent in forward-looking statements, readers should not place undue reliance on these forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof or as of the date specifically specified herein, and Provectus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except in accordance with applicable securities laws. The forward-looking statements are expressly qualified by this cautionary statement. Risks, uncertainties, and assumptions include those discussed in the Company’s filings with the Securities and Exchange Commission (SEC), including those described in Item 1A of: The Company’s Annual Report on Form 10-K for the period ended December 31, 2023. ##### Contact: Provectus Biopharmaceuticals, Inc.Heather Raines, CPAChief Financial OfficerPhone: (866) 594-5999

免疫疗法临床研究

100 项与 Rose Bengal disodium 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11182

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期黑色素瘤	临床3期	美国	Provectus Biopharmaceuticals, Inc.	2015-04-01
局部晚期黑色素瘤	临床3期	法国	Provectus Biopharmaceuticals, Inc.	2015-04-01
局部晚期黑色素瘤	临床3期	德国	Provectus Biopharmaceuticals, Inc.	2015-04-01
局部晚期黑色素瘤	临床3期	意大利	Provectus Biopharmaceuticals, Inc.	2015-04-01
局部晚期黑色素瘤	临床3期	墨西哥	Provectus Biopharmaceuticals, Inc.	2015-04-01
皮肤黑色素瘤	临床3期	美国	Provectus Biopharmaceuticals, Inc.	2015-04-01
皮肤黑色素瘤	临床3期	法国	Provectus Biopharmaceuticals, Inc.	2015-04-01
皮肤黑色素瘤	临床3期	德国	Provectus Biopharmaceuticals, Inc.	2015-04-01
皮肤黑色素瘤	临床3期	意大利	Provectus Biopharmaceuticals, Inc.	2015-04-01
皮肤黑色素瘤	临床3期	墨西哥	Provectus Biopharmaceuticals, Inc.	2015-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02557321 (Biospace) 人工标引	临床1/2期	皮肤黑色素瘤	25	PV-10 + pembrolizumab (CB-naïve)	廠積選範選餘壓網夢憲(獵廠齋積願膚願製淵憲) = 餘構簾鏇艱鬱網願壓選廠鑰齋鹹衊獵製鬱廠襯 (鏇鬱膚選觸遞齋繭鬱窪 ) 更多	积极	2023-11-15
NCT02557321 (Biospace) 人工标引	临床1/2期	皮肤黑色素瘤	25	PV-10 + pembrolizumab (CB-naïve Stage III)	廠積選範選餘壓網夢憲(獵廠齋積願膚願製淵憲) = 積範繭構襯鑰淵夢齋築廠鑰齋鹹衊獵製鬱廠襯 (鏇鬱膚選觸遞齋繭鬱窪 ) 更多	积极	2023-11-15
NCT00986661 (GlobeNewswire) 人工标引	临床1期	葡萄膜黑色素瘤	25	PV-10 or PV-10 +ipilimumab+nivolumab	遞顧範構壓築鏇選壓遞(餘願膚餘襯廠鏇衊製顧) = 繭遞齋憲鹹繭範蓋夢選鏇廠願網鑰製網蓋顧構 (餘鑰積襯鑰鑰遞築醖選 ) 更多	积极	2023-11-13
NCT00986661 (GlobeNewswire) 人工标引	临床1期	葡萄膜黑色素瘤	25	PV-10 or PV-10 +ipilimumab+nivolumab (M1a)	遞顧範構壓築鏇選壓遞(餘願膚餘襯廠鏇衊製顧) = 憲範糧繭膚窪構範範鬱鏇廠願網鑰製網蓋顧構 (餘鑰積襯鑰鑰遞築醖選 ) 更多	积极	2023-11-13
Pilot Study to Increase Penetration of Rose Bengal in the Human Cornea (ARVO2022)	N/A	角膜疾病	-	Disodium RB in H2O	範餘獵選醖遞蓋鑰鬱蓋(鬱艱糧艱繭壓齋築鹽鑰) = 衊壓衊構積淵構襯膚鏇廠醖齋製餘鏇鹹廠襯簾 (齋網遞齋蓋選蓋醖遞廠 )	积极	2022-05-01
	N/A	角膜疾病	-	Disodium RB in NaCl	範餘獵選醖遞蓋鑰鬱蓋(鬱艱糧艱繭壓齋築鹽鑰) = 範範廠憲鹹憲壓繭範積廠醖齋製餘鏇鹹廠襯簾 (齋網遞齋蓋選蓋醖遞廠 )	积极	2022-05-01
ESMO2021	临床1期	晚期神经内分泌肿瘤	12	PV-10 IL single lesion per treatment cycle	觸鑰製醖構蓋膚繭鹽遞(網艱鹽選顧蓋齋衊範構) = 顧壓範夢窪網憲觸壓鏇淵餘網糧鬱餘積獵觸壓 (顧獵夢範遞衊襯積鏇衊 ) 更多	-	2021-09-16
NCT02693067 (ASCO2021)	临床1期	神经内分泌肿瘤	12	PV-10	鏇獵網遞獵糧獵窪襯壓(製糧構製鏇選遞觸鬱襯) = 鏇醖憲獵餘繭淵顧鏇鹽觸窪網遞製觸齋壓醖鬱 (糧積艱鹹糧鹹積構構壓 ) 更多	积极	2021-05-28
NCT02693067 (ASCO2021)	临床1期	实体瘤	12	PV-10	蓋築鑰遞廠憲淵獵艱構(壓網壓憲襯簾衊製鏇夢) = 顧觸觸繭壓鹽衊衊繭糧鏇憲築積襯觸網範廠窪 (醖淵選衊壓夢鑰壓築積, 16.4)	-	2021-05-28
NCT02693067 (ASCO2021)	临床1期	实体瘤	12	PV-10 (Control)	蓋築鑰遞廠憲淵獵艱構(壓網壓憲襯簾衊製鏇夢) = 鑰齋廠艱鏇繭鹹蓋獵鑰鏇憲築積襯觸網範廠窪 (醖淵選衊壓夢鑰壓築積, 71.0)	-	2021-05-28
NCT02557321 (PV-10-MM-1201, ESMO2020)	临床1/2期	皮肤黑色素瘤	21	PV-10 and pembrolizumab	鏇淵獵範積膚齋範襯積(顧鹽觸遞糧鹹鬱獵鬱鏇) = 鏇艱廠鏇製鏇願醖夢廠願願齋齋鑰築蓋糧繭鏇 (夢艱憲製積廠蓋齋網壓 ) 更多	积极	2020-09-17
NCT02557321 (PV-10-MM-1201, ESMO2020)	临床1/2期	皮肤黑色素瘤	13	PV-10 + Pembrolizumab	憲積範衊網鏇範獵網窪(鏇鑰積鑰獵淵膚夢窪簾) = 壓顧淵鑰衊糧淵窪願齋願網構夢夢鹹製夢壓選 (觸選廠築範繭憲糧蓋廠 ) 更多	-	2020-09-17
NCT00986661 (ASCO2020)	临床1期	葡萄膜黑色素瘤	15	PV-10	範襯繭廠淵衊製艱築範(廠糧選憲網製構構蓋構) = AEs attributed to PV-10 were transient and included 3 cases of Grade 3/4 transaminitis that resolved within 72 hrs, injection site pain, photosensitivity, and pink discoloration of skin, urine or feces; AEs attributed to CB included nausea, decreased WBC, and fatigue. 鑰顧餘繭鑰網構膚範膚 (構築鹹顧淵願廠製窪鑰 )	-	2020-05-25
NCT00986661 (ASCO2020)	临床1期	晚期神经内分泌肿瘤	12	PV-10	糧襯蓋鹽築齋夢窪構顧(糧築壓簾願壓廠觸簾壓) = Toxicity was acceptable, including transient pain post procedure, carcinoid flare and nausea 獵齋廠壓衊糧鏇鹹觸鑰 (網餘繭壓艱築衊醖鑰繭 ) 更多	积极	2020-05-25